Does Blue Cross Blue Shield of North Carolina Cover Lantus?

How BCBSNC Formulary Placement Works for Lantus

BCBSNC organizes covered medications into a tiered formulary that directly determines what you pay at the pharmacy counter. Lantus (insulin glargine U-100), manufactured by Sanofi, appears on multiple BCBSNC plan formularies but its exact tier can shift between plan years and product lines.

Most BCBSNC commercial plans place Lantus on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). The distinction matters. A Tier 3 placement might carry a $40 to $60 copay per 30-day supply, while a Tier 4 placement could mean coinsurance of 25% to 40% after deductible. BCBSNC publishes its formulary lists annually, and members can search the drug formulary tool on the BCBSNC member portal to confirm their plan's current tier for Lantus.

Insulin glargine has been available since the FDA approved Lantus in 2000, making it one of the longest-standing basal insulin analogs on the market. A meta-analysis of 25 randomized controlled trials (N=7,028) confirmed that insulin glargine produces comparable glycemic control to NPH insulin with significantly fewer nocturnal hypoglycemic episodes [1]. That efficacy profile is one reason insurers continue to include it, even as biosimilars have entered the market.

Your plan documents (the Summary of Benefits and Coverage, or SBC) are the definitive source for your specific tier placement and cost-sharing structure.

The $35 Monthly Insulin Cap and What It Means for Your Lantus Prescription

The Inflation Reduction Act (IRA), signed into law in August 2022, capped out-of-pocket insulin costs at $35 per month for Medicare Part D enrollees beginning January 1, 2023 [2]. This applies to all Part D covered insulins, including Lantus, regardless of whether the enrollee has met their deductible.

The cap changed everything for Medicare beneficiaries. Before the IRA, Medicare enrollees paid an average of $54.60 per insulin fill according to a Kaiser Family Foundation analysis. Some patients on high-deductible plans faced costs exceeding $300 per month for Lantus.

For BCBSNC Medicare Advantage (Blue Medicare) plans, the $35 cap is mandatory. BCBSNC has also voluntarily extended insulin cost-sharing limits to many of its ACA marketplace plans sold through HealthCare.gov in North Carolina. The North Carolina General Assembly considered but did not pass a state-level $50 insulin copay cap bill (HB 263) during the 2023-2024 session, so commercial fully-insured plans without a voluntary cap are not bound by a state statute.

If you have a BCBSNC commercial employer plan, your insulin cost depends on your employer's benefit design. Self-funded employer plans set their own formulary rules and are not subject to state insurance mandates, though many have voluntarily adopted similar caps.

Biosimilar Alternatives That BCBSNC May Prefer Over Brand Lantus

BCBSNC, like most large insurers, has been shifting formulary preference toward lower-cost insulin glargine biosimilars. Three biosimilar or follow-on alternatives to Lantus are currently on the market.

Basaglar (insulin glargine, Eli Lilly) received FDA approval in 2015 as a follow-on biologic. It is not technically classified as a biosimilar under the 351(k) pathway but is therapeutically equivalent. BCBSNC frequently places Basaglar on a preferred brand tier below Lantus.

Semglee (insulin glargine-yfgn, Viatris/Biocon) became the first interchangeable biosimilar insulin in 2021. Interchangeable designation means pharmacists in North Carolina can substitute Semglee for Lantus at the pharmacy without contacting the prescriber, subject to state substitution laws. Semglee often appears on Tier 2 (preferred brand) on BCBSNC formularies, offering lower cost-sharing than brand Lantus.

Rezvoglar (insulin glargine-aglr, Eli Lilly) received FDA approval as a biosimilar to Lantus. Lilly has priced it competitively, and some BCBSNC plans place it alongside or below Basaglar.

A 52-week randomized trial (ELEMENT 1, N=535) demonstrated that Basaglar and Lantus produced equivalent A1C reductions in type 1 diabetes, with no clinically meaningful differences in hypoglycemia rates or immunogenicity [3]. The clinical evidence supporting biosimilar interchangeability means switching from Lantus to a preferred biosimilar is both safe and often financially advantageous.

If your BCBSNC plan places Lantus on a higher tier, ask your prescriber whether switching to the plan's preferred insulin glargine product makes clinical sense. The active molecule is identical.

Prior Authorization and Step Therapy Requirements

Some BCBSNC plans require prior authorization (PA) before covering brand Lantus, particularly when a biosimilar is the preferred formulary option. Step therapy protocols may require you to try and document inadequate response or intolerance to a preferred alternative before BCBSNC will approve brand Lantus at a lower cost-sharing level.

The PA process at BCBSNC typically involves your prescriber submitting clinical documentation showing medical necessity for brand Lantus specifically. Common acceptable reasons include documented adverse reaction to a biosimilar, dosing precision concerns with pen devices (Lantus SoloStar vs. biosimilar pen designs), or pharmacy availability issues.

BCBSNC publishes its prior authorization criteria in clinical policies available on the provider portal. Turnaround time for a standard PA request is generally 5 to 7 business days. Urgent requests tied to immediate medical need must be processed within 24 hours under North Carolina Department of Insurance regulations.

If your PA is denied, BCBSNC provides a formal appeals process. The American Diabetes Association's Standards of Care recommend that insulin access should not be delayed by administrative barriers, and citing this guideline in an appeal can strengthen your case [4]. Your prescriber can also request a peer-to-peer review with a BCBSNC medical director.

What You Will Actually Pay: Real Cost Scenarios

Understanding your out-of-pocket cost for Lantus on a BCBSNC plan requires knowing your plan type, tier placement, and deductible status. Here are realistic scenarios based on common BCBSNC plan designs.

BCBSNC Blue Medicare HMO/PPO: The IRA $35 monthly cap applies. You pay no more than $35 for a 30-day Lantus supply regardless of tier or deductible. This applies at both preferred and non-preferred pharmacies, though using an in-network pharmacy is required.

BCBSNC ACA Marketplace (Blue Value/Blue Local/Blue Select): Most current marketplace plans cap insulin at $35 per month. Verify on your plan's Summary of Benefits, as this voluntary cap can change by plan year.

BCBSNC Commercial Employer Plan (Fully Insured): Lantus on Tier 3 typically costs $40 to $60 copay or 25% coinsurance. On Tier 4, expect $75 to $100 copay or 30% to 40% coinsurance. If the plan has a combined medical/pharmacy deductible, you may pay full price until the deductible is met.

BCBSNC Self-Funded Employer Plan: Costs vary widely. The employer sets the formulary and cost-sharing structure. Contact your HR benefits team for specifics.

The list price of Lantus was reduced by Sanofi in 2024 to $78 per vial (down from a WAC of approximately $283 per vial), following pressure from the insulin pricing debate [5]. This list price reduction flows through to lower out-of-pocket costs for patients in coinsurance-based plans.

A study published in JAMA Internal Medicine found that 1 in 4 insulin users reported cost-related nonadherence, with rationing behaviors including skipping doses and using less than prescribed amounts [6]. If cost is a barrier, exploring your plan's preferred alternatives or patient assistance programs can prevent dangerous gaps in basal insulin coverage.

How to Verify Your Specific BCBSNC Lantus Coverage

Do not assume your plan covers Lantus at the tier described in general formulary documents. BCBSNC administers dozens of distinct plan products across commercial, marketplace, and Medicare lines. Verification takes three steps.

Step 1: Check the BCBSNC online formulary. Log into your BCBSNC member account at bcbsnc.com. Manage to "Find a Drug" or "Formulary Search" and enter "Lantus" or "insulin glargine." The tool will return your plan-specific tier, quantity limits, and any PA requirements.

Step 2: Call BCBSNC Member Services. The number on the back of your member ID card connects you to a representative who can confirm real-time coverage details, including whether your plan participates in the $35 insulin cap. Ask specifically: "Is Lantus on my plan's formulary, and what is my cost-sharing at a preferred pharmacy?"

Step 3: Ask your pharmacist to run a test claim. A pharmacy can process a trial adjudication to show your exact copay before you commit to filling. This is the most reliable way to see your true out-of-pocket cost, as it reflects your current deductible status and any plan-specific pricing.

The CDC reports that approximately 37.3 million Americans have diabetes and about 8.4 million use insulin [7]. Among insulin users, basal insulins like Lantus represent the most commonly prescribed category. Knowing your exact coverage prevents the kind of sticker shock that leads to prescription abandonment.

Patient Assistance and Savings Programs for Lantus

Even with insurance, copays for Lantus can strain household budgets. Several programs exist to reduce costs for BCBSNC members and uninsured patients in North Carolina.

Sanofi Insulins Valyou Savings Program: Uninsured patients or those with commercial insurance (not government plans) can pay as little as $35 per 30-day Lantus prescription. No income verification is required. This program does not apply to Medicare, Medicaid, or TRICARE beneficiaries.

Sanofi Patient Connection: For patients at or below 400% of the federal poverty level who lack prescription coverage, Sanofi provides free Lantus through this program. Applications require prescriber involvement and income documentation.

BCBSNC PrudentRx Program: Some BCBSNC plans participate in PrudentRx or similar copay optimization programs that can reduce specialty tier costs. Check your plan documents for participation.

340B Pharmacy Pricing: If you receive care at a federally qualified health center (FQHC) or qualifying hospital outpatient pharmacy in North Carolina, 340B pricing may reduce your Lantus cost significantly. North Carolina has 42 FQHCs with multiple sites statewide.

The Endocrine Society's 2023 clinical practice guideline on type 2 diabetes pharmacotherapy emphasizes that cost should be a factor in insulin selection and that clinicians should help patients identify the most affordable insulin option within the same drug class [8]. Prescribers who understand your BCBSNC plan's formulary preferences can steer toward the lowest-cost insulin glargine product without compromising glycemic outcomes.

"The choice between branded Lantus and a biosimilar insulin glargine should be driven by patient access and affordability, not brand loyalty. These products deliver equivalent glycemic control," stated the Endocrine Society guideline committee in their 2023 update [8].

Lantus vs. Other Long-Acting Insulins on BCBSNC Formularies

Lantus is not the only long-acting insulin available to BCBSNC members. Understanding where each option sits on the formulary can save hundreds of dollars annually.

Levemir (insulin detemir): Another long-acting insulin with a different molecular structure. Some BCBSNC plans place Levemir on a preferred tier when they have a contract with Novo Nordisk. The PREDICTIVE 303 study (N=5,604) showed comparable real-world glycemic control between insulin glargine and insulin detemir, though detemir often requires twice-daily dosing [9].

Toujeo (insulin glargine U-300): A concentrated formulation of insulin glargine made by Sanofi. Toujeo provides a flatter pharmacokinetic profile and may reduce nocturnal hypoglycemia compared to Lantus. The EDITION trials demonstrated non-inferior A1C reduction with less hypoglycemia [10]. BCBSNC typically places Toujeo on a higher tier than Lantus due to its brand-only status and higher list price.

Tresiba (insulin degludec): An ultra-long-acting insulin with a half-life exceeding 25 hours. The DEVOTE trial (N=7,637) showed cardiovascular safety non-inferiority to Lantus [11]. Tresiba sits on Tier 4 or specialty tier on most BCBSNC plans, making it a more expensive option.

For most patients with type 2 diabetes, switching between long-acting insulins produces equivalent A1C outcomes. The practical decision often comes down to which product your BCBSNC plan covers at the lowest cost.

"Insulin affordability remains a primary concern for patients and clinicians. When formulary restrictions limit access to a specific insulin, therapeutic alternatives within the same class should be offered promptly," noted the American Diabetes Association's 2024 Standards of Care [4].

North Carolina Pharmacy Laws That Affect Your Lantus Fill

North Carolina has specific pharmacy substitution laws that interact with your BCBSNC insulin coverage. The state permits pharmacist-initiated substitution of interchangeable biosimilars (like Semglee for Lantus) unless the prescriber writes "Dispense As Written" (DAW) on the prescription.

If your prescriber does not indicate DAW and your BCBSNC plan prefers a biosimilar, the pharmacist may substitute automatically. This can lower your copay. If you or your prescriber prefer brand Lantus specifically, a DAW designation protects against substitution but may result in higher cost-sharing and a potential PA requirement.

North Carolina does not currently have a state-mandated insulin copay cap, unlike states such as Colorado (which capped insulin copays at $100 per month in 2019, later reduced to $50). Federal protections under the IRA apply only to Medicare and, through voluntary insurer adoption, some commercial plans.

The North Carolina Department of Insurance oversees fully-insured health plans in the state. Complaints about formulary access or PA delays for medically necessary insulin can be filed through the NCDOI Consumer Services Division.